Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 56
Treatment-assignment count: 0
Stratification count: 0
breast cancer · Combination Therapy
MET exon 14 skipping is flagged as trial selection rising because public trials show inclusion required evidence in 63 contexts. FDA CDx context should be reviewed manually.
Strongest role: Inclusion Required
Inclusion-required count: 56
Treatment-assignment count: 0
Stratification count: 0
Threshold count: 0
Common snippets: None extracted
Threshold label: Low
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: Medium
Signal count: 0
Recent signals: 0
Density label: Low
https://clinicaltrials.gov/study/NCT07153965 | https://clinicaltrials.gov/study/NCT00422903 | https://clinicaltrials.gov/study/NCT04726332 | https://clinicaltrials.gov/study/NCT00057941 | https://clinicaltrials.gov/study/NCT02536742 | https://clinicaltrials.gov/study/NCT01151046 | https://clinicaltrials.gov/study/NCT05253053 | https://clinicaltrials.gov/study/NCT02630368 | https://clinicaltrials.gov/study/NCT00517361 | https://clinicaltrials.gov/study/NCT02897986 | https://clinicaltrials.gov/study/NCT07544056 | https://clinicaltrials.gov/study/NCT01281150 | https://clinicaltrials.gov/study/NCT01251874 | https://clinicaltrials.gov/study/NCT03202316 | https://clinicaltrials.gov/study/NCT00093145 | https://clinicaltrials.gov/study/NCT04975308 | https://clinicaltrials.gov/study/NCT01118975 | https://clinicaltrials.gov/study/NCT00373256 | https://clinicaltrials.gov/study/NCT02041429 | https://clinicaltrials.gov/study/NCT07054190 | https://clinicaltrials.gov/study/NCT05631795 | https://clinicaltrials.gov/study/NCT04130152 | https://clinicaltrials.gov/study/NCT07405801 | https://clinicaltrials.gov/study/NCT02676986 | https://clinicaltrials.gov/study/NCT02955394 | https://clinicaltrials.gov/study/NCT01439282 | https://clinicaltrials.gov/study/NCT00331630 | https://clinicaltrials.gov/study/NCT02115048 | https://clinicaltrials.gov/study/NCT03505528 | https://clinicaltrials.gov/study/NCT04113863 | https://clinicaltrials.gov/study/NCT02941926 | https://clinicaltrials.gov/study/NCT05904730 | https://clinicaltrials.gov/study/NCT06857747 | https://clinicaltrials.gov/study/NCT06394661 | https://clinicaltrials.gov/study/NCT03395899 | https://clinicaltrials.gov/study/NCT03283384 | https://clinicaltrials.gov/study/NCT04872985 | https://clinicaltrials.gov/study/NCT07029399 | https://clinicaltrials.gov/study/NCT00499083 | https://clinicaltrials.gov/study/NCT03969121 | https://clinicaltrials.gov/study/NCT03128619 | https://clinicaltrials.gov/study/NCT05573126 | https://clinicaltrials.gov/study/NCT01207102 | https://clinicaltrials.gov/study/NCT01919229 | https://clinicaltrials.gov/study/NCT02007512 | https://clinicaltrials.gov/study/NCT06516289 | https://clinicaltrials.gov/study/NCT00440622 | https://clinicaltrials.gov/study/NCT02520063 | https://clinicaltrials.gov/study/NCT05810870 | https://clinicaltrials.gov/study/NCT04293393 | https://clinicaltrials.gov/study/NCT07189884 | https://clinicaltrials.gov/study/NCT05837455 | https://clinicaltrials.gov/study/NCT05967884 | https://clinicaltrials.gov/study/NCT02001974 | https://clinicaltrials.gov/study/NCT07187674 | https://clinicaltrials.gov/study/NCT02511847 | https://clinicaltrials.gov/study/NCT05068141 | https://clinicaltrials.gov/study/NCT06067061 | https://clinicaltrials.gov/study/NCT07045311 | https://clinicaltrials.gov/study/NCT06889688 | https://clinicaltrials.gov/study/NCT04913571 | https://clinicaltrials.gov/study/NCT01953536 | https://clinicaltrials.gov/study/NCT01606241